Update on molecular findings, management and outcome in low-grade gliomas

Bourne, T. David; Schiff, David

doi:10.1038/nrneurol.2010.159

Cited by 131 publications

(89 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with Yan et al, 2009 [29] who found all studied oligoastrocytoma cases 10/10 (100%) stained diffusely with IDH1. These results were also in agreement to Bourne and Schiff 2010 [30] who reported that IDH1 expression in mixed oligoastrocytomas was ranged from 50% to 100%. As regard to epidermal growth factor receptor expression (EGFR); it was highly significant in distinguishing diffuse astrocytoma WHO grade II from reactive astrocytosis (Pvalue=0.00014).…”

Section: Resultssupporting

confidence: 93%

Evaluation of the Role of Mutant Idh1, Egfr and Bcl2 Protein Expression in Distinguishing Diffuse Astrocytoma From Astrocytosis

Saba

Rashed

et al. 2014

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Gliomas are the most relevant primary brain tumors. Diffuse astrocytomas are the most common type of gliomas .The distinction of diffuse infiltrating astrocytoma from reactive astrocytosis is one of the most difficult differential diagnosis especially with small biopsies (e.g. stereotactic biopsies). Several markers were used for this differentiation such as glial fibrillary acidic protein, ki67 and p53; but each of them has problems with sensitivity and specificity. The immunohistochemical markers such as mutant isocitrate dehydrogenase 1 (IDH1), EGFR and Bcl2 may be useful in this differentiation. Aim: This study was conducted to clarify the value of IDH1, EGFR and Bcl2 protein expression in making a clear distinction between diffuse infiltrating astrocytomas and morphologically similar reactive astrocytosis. Methods: Fifty representative cases; 30 cases WHO grade II diffuse astrocytomas and 20 cases of reactive conditions were examined immunohistochemically using antibodies against mutant IDH1, EGFR and Bcl2. Results: IDH1 was positive in 60% of astrocytomas cases but it was totally absent in reactive astrocytosis. EGFR was expressed in 50% of astrocytomas; but it was not expressed in reactive astrocytosis. Bcl2 expression was detected in 56.7% of astrocytomas cases. However; it was expressed also in 75% of reactive astrocytosis cases. Conclusion: IDH1, EGFR were the most useful IHC markers in the discrimination of low grade diffuse astrocytomas WHO II from reactive astrocytosis; particularly in small biopsies. Bcl2 play no role in this differentiation

show abstract

Section: Resultssupporting

confidence: 93%

Evaluation of the Role of Mutant Idh1, Egfr and Bcl2 Protein Expression in Distinguishing Diffuse Astrocytoma From Astrocytosis

Saba

Rashed

et al. 2014

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…Finally, molecular markers, which are increasingly used for the assessment and management of LGG, were not included in the statistical analysis due to their recent introduction in clinical practice. 8 Ongoing and future randomized trials of LGG treatment will offer the opportunity to reveal the possible relationships between the molecular profiles and seizure outcome, detecting the histological subtypes more likely to result in drug-resistant epilepsy.…”

Section: Clinical Role Of Peritumoral Infiltrated Tissuementioning

confidence: 99%

Surgery for insular low-grade glioma: predictors of postoperative seizure outcome

Ius

Pauletto

Isola

et al. 2014

JNS

View full text Add to dashboard Cite

Object. Although a number of recent studies on the surgical treatment of insular low-grade glioma (LOG) have demonstrated that aggressive resection leads to increased overall patient survival and decreased malignant progression, less attention has been given to the results with respect to tumor-related epilepsy. The aim of this investigation was to evaluate the impact of volumetric, histological, and intraoperative neurophysiological factors on seizure outcome in patients with insular LGG. \ud Methods. The authors evaluated predictors of seizure outcome with special emphasis on both the extent of tumor resection (EOR) and the tumor's infiltrative pattern quantified by computing the difference between the preoperative T2- and Ti-weighted MR images (Delta VT2T1) in 52 patients with preoperative drug-resistant epilepsy. \ud Results. The 12-month postoperative seizure outcome (Engel class) was as follows: seizure free (Class I), 67.31%; rare seizures (Class II), 7.69%; meaningful seizure improvement (Class III), 15.38%; and no improvement or worsening (Class IV), 9.62%. Poor seizure control was more common in patients with a longer preoperative seizure history (p < 0.002) and higher frequency of seizures (p = 0.008). Better seizure control was achieved in cases with EOR >= 90% (p < 0.001) and Delta VT2T1 < 30 cm(3) (p < 0.001). In the final model, Delta VT2T1 proved to be the strongest independent predictor of seizure outcome in insular LGG patients (p < 0.0001). \ud Conclusions. No or little postoperative seizure improvement occurs mainly in cases with a prevalent infiltrative tumor growth pattern, expressed by high Delta VT2T1 values, which consequently reflects a smaller BOR

show abstract

“…4 Molecular markers involved in low-grade glioma pathways also play a critical role in determining prognosis. 5,6 The TP53 mutation is an early event in genetic pathogenesis that occurs in all types of cancer. The incidence of TP53 mutation in…”

mentioning

confidence: 99%

Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis

Wang

Zhang²,

et al. 2014

American Journal of Neuroradiology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Brain tumor location has proved to be a prognostic factor that may be associated with features of neoplastic origin. Mutation of p53 is an atypical genetic change that occurs during tumorigenesis. Thus, a potential correlation may exist between tumor location and p53 status. The purpose of the current study was to identify anatomic characteristics of mutant p53 expression by using quantitative neuroimaging analyses.

show abstract

Update on molecular findings, management and outcome in low-grade gliomas

Cited by 131 publications

References 92 publications

Evaluation of the Role of Mutant Idh1, Egfr and Bcl2 Protein Expression in Distinguishing Diffuse Astrocytoma From Astrocytosis

Evaluation of the Role of Mutant Idh1, Egfr and Bcl2 Protein Expression in Distinguishing Diffuse Astrocytoma From Astrocytosis

Surgery for insular low-grade glioma: predictors of postoperative seizure outcome

Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis

Contact Info

Product

Resources

About